MAZE
Maze Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$28.37+0.89%
Price as of Jul 20, 2026
MAZE financials
Maze Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $167.5M | $0.00 | $0.00 |
| Cost of revenue | $2.4M | $0.00 | $0.00 | $0.00 |
| Gross profit | -$2.4M | $167.5M | $0.00 | $0.00 |
| Operating expenses | $140.5M | $109.9M | $98.6M | $111.0M |
| Operating income | -$142.9M | $57.6M | -$98.6M | -$111.0M |
| Net income | -$131.1M | $52.2M | -$100.4M | -$114.9M |
| EBITDA | -$128.7M | $56.7M | -$96.3M | -$111.1M |
| Basic EPS | $-3.05 | $0.08 | $-2.29 | $-2.63 |
| Diluted EPS | $-3.05 | $0.08 | $-2.29 | $-2.63 |
| Balance sheet | ||||
| Cash & equivalents | $189.2M | $196.8M | $29.2M | $99.9M |
| Total assets | $397.1M | $240.5M | $71.5M | $150.0M |
| Total liabilities | $42.2M | $43.6M | $61.5M | $48.5M |
| Stockholders’ equity | $355.0M | $196.9M | $10.1M | $101.4M |
| Total debt | $23.3M | $26.6M | $49.6M | $32.1M |
| Net debt | -$165.9M | -$170.2M | $20.5M | -$67.9M |
| Cash flow | ||||
| Operating cash flow | -$111.9M | $76.0M | -$86.8M | -$99.2M |
| Capital expenditure | -$794.0K | -$1.1M | -$441.0K | -$2.0M |
| Free cash flow | -$112.7M | $74.8M | -$87.3M | -$101.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |